Skip to main content

Biogen statistics

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.52B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Biogen is valued at $37.52B on its latest close. Its price is 108.0 times its earnings.

Market value$37.52B
Enterprise value$43.56B
Price / earnings107.98
Price / sales3.64
Price / book1.98
EV / EBITDA26.68
EV / sales4.23
Price / free cash flow18.12
Price / free cash flow, own 5-year average17.64
EV / EBIT58.11
EV / free cash flow21.07
Free cash flow yield5.5%

Share price

Latest close$253.40
Day's change+1.2%
52-week high$261.00
52-week low$160.36
From 52-week high−2.9%
Return · 1 month+8.9%
Return · 3 months+18.2%
Return · year to date+44.0%
Return · 1 year+56.9%
Beta · 1 year against the S&P 5000.37
50-day average$233.35
200-day average$205.15
RSI 1459.1
Average volume · 20 sessions1.2M

Margins and returns

For fiscal 2025, as filed.

Gross margin75.7%
Operating margin18.8%
Net margin13.1%
Free cash flow margin20.7%
Return on equity7.4%
Return on assets5.4%
Return on invested capital6.9%
Return on invested capital, 5-year average11.5%
Return on capital employed7.7%
Stock-based compensation / revenue2.9%

Financial position

At the end of fiscal 2025.

Cash and equivalents$3.01B
Total debt$6.66B
Net debt$2.84B
Current ratio2.68
Quick ratio0.33
Debt / equity0.36
Net debt / EBITDA1.08
Interest coverage6.96

Growth

Revenue, latest quarter on a year+10.6%
Revenue, twelve months on a year+2.3%
EPS, latest quarter on a year−104%
EPS, twelve months on a year−78.7%
Revenue, 5-year compound−6.0%
Revenue, 10-year compound−0.8%
Net income, 5-year compound−20.2%
Free cash flow, 5-year compound−11.6%
EPS, 5-year compound−18.7%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares147M
Shares outstanding, 5-year compound−1.8%

Taxes

For fiscal 2025, as filed.

Income tax expense$263.6M
Effective tax rate16.9%

BIIB in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.